Medical/Pharmaceuticals

RingConn Launches Gen 2 Smart Ring: Pioneering Sleep Apnea Detection with Unmatched 10 - 12 Days Battery Life

World's Leading Provider of Cutting-Edge Smart Ring Solutions NEW YORK, Aug. 2, 2024 /PRNewswire/ -- RingConn today launches its Gen 2 Smart Ring on Kickstarter, featuring the first-ever integrated sleep apnea monitoring in a smart ring. This groundbreaking device offers ...

2024-08-02 00:00 7872

TraceLink and Tecsys Collaboration Brings Advanced Supply Chain Management to Health Systems

BOSTON and MONTREAL, Aug. 1, 2024 /PRNewswire/ -- TraceLink Inc., the largest end-to-end intelligent supply chain platform for life sciences and healthcare, today announced a strategic partnership with Tecsys, a global leader in supply chain management solutions. For healthcare systems, a lack of...

2024-08-01 22:30 3157

1,000+ Medical Device Manufacturing Leaders Gather at Medtec 2024

Experts Deliver Key Insights into Industry Trends SHANGHAI, Aug. 1, 2024 /PRNewswire/ -- The Government Work Report releases in early 2024 emphasized the need to "explore new avenues in life sciences." As a key area for developing new productivity, the medical device industry encompasses both th...

2024-08-01 18:30 1920

The Director General of Pharmaceuticals and Medical Devices Visits Fapon in Indonesia

JAKARTA, Indonesia, Aug. 1, 2024 /PRNewswire/ -- The Ministry of Health of the Republic ofIndonesia, represented by the Director General of Pharmaceuticals and Medical Devices (Dirjen Falmakes), Dr. Dra. Lucia Rizka Andalucia, along with the Director of Medical Device Production and Distribution ...

2024-08-01 16:52 4157

Innovent Announces the NDA of Mazdutide for Type 2 Diabetes has been Accepted by the NMPA of China

SAN FRANCISCO, U.S. and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and meta...

2024-08-01 16:40 4396

Biosyngen Partners with Singapore's Agency for Science, Technology and Research (A*STAR) to Advance Autoimmune Therapy

GUANGZHOU, China, Aug. 1, 2024 /PRNewswire/ -- Biosyngen has announced a strategic collaboration withSingapore's Agency for Science, Technology and Research (A*STAR) to enhance autoimmune therapy. The partnership was signed during the 14th Meeting of the Singapore-Guangdong Collaboration Council,...

2024-08-01 16:01 4621

Sirnaomics Announces a Partnership with Gore Range Capital for Establishment of a JV, Sagesse Bio, to Advance Its RNAi Therapeutics into Aesthetic Medicine

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today ...

2024-08-01 11:26 5310

Sirnaomics Announces a Partnership with Gore Range Capital for Establishment of a JV, Sagesse Bio, to Advance Its RNAi Therapeutics into Aesthetic Medicine

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, to...

2024-08-01 09:35 2672

Prestige Biopharma's Herceptin Biosimilar Tuznue® Receives Positive CHMP Opinion from the EMA

* Following approval by the European Commission, Prestige Biopharma's Herceptin biosimilar Tuznue® would become the first biosimilar from a Singaporean company to be authorized in the European Union. SINGAPORE, Aug. 1, 2024 /PRNewswire/ -- Prestige Biopharma, a pioneer in biopharmaceuticals, a...

2024-08-01 08:00 15267

PROCESSED RED MEAT RAISES THE RISK OF DEMENTIA; SWAPPING IT FOR NUTS AND BEANS MAY LOWER RISK

Four-decade study of more than 130,000 people measured the risk of your morning bacon or ballgame hot dog Key Takeaways * Eating about two servings per week of processed red meat raises the risk of dementia by 14% compared to those who eat less than approximately three servings a month. * S...

2024-07-31 19:00 3783

Kexing Biopharm's Albumin-bound Paclitaxel Granted EU Market Approval

SHENZHEN, China, July 31, 2024 /PRNewswire/ -- On July 28 2024, Kexing Biopharm announced European Commission approval of Apexelsin®, the generic drug to Bristol Myers Squibb's and Celgene's Abraxane®(Nab-paclitaxel). Apexelsin® is developed by WhiteOak Pharmaceutical B.V. and Kexing Biopharm is ...

2024-07-31 18:33 4747

Connext Successfully Administers First Dose of CNT201 for Dupuytren's Contracture

World's First Genetically Recombinant Collagenase Therapeutics (CNT201) Begins Clinical Trials inAustralia SEOUL, South Korea, July 30, 2024 /PRNewswire/ -- Connext has announced the successful first administration of CNT201, its therapeutic treatment for Dupuytren's contracture, in patients. D...

2024-07-30 21:00 3412

Sengenics Corporation Unveils i-Ome® Cancer: A Breakthrough in Cancer Precision Medicine

Revolutionizing Biomarker Discovery with a High-Throughput Immunoproteomic Platform BOSTON, July 30, 2024 /PRNewswire/ -- Sengenics Corporation LLC is proud to announce the launch of i-Ome Cancer, a cutting-edge research tool designed to transform cancer biomarker discovery using just a drop of ...

2024-07-30 20:30 3737

GLP-1 DRUG LIRAGLUTIDE MAY PROTECT AGAINST DEMENTIA

Key Takeaways * A GLP-1 agonist — the class of drugs shown to help with diabetes and weight loss and reduce the risk of heart disease — also may protect the brain. * In a Phase 2b trial, liraglutide appears to reduce shrinking in the parts of the brain that control memory, learning, language ...

2024-07-30 19:00 3868

Clarivate Introduces New OFF-X ™ Platform for Preclinical and Clinical Safety Intelligence

Empowering biopharma with enhanced safety insights to anticipate risks and unlock new competitive advantages LONDON, July 30, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the launch of the newOFF-X™ platform. The enhance...

2024-07-30 15:00 2908

Baxter's Helion System Launches in Thailand, Bringing Comprehensive Simplicity to ORs

BANGKOK, July 30, 2024 /PRNewswire/ -- Baxter International Inc . (NYSE: BAX), a global MedTech leader, announced the launch of theHelion Integrated Surgical System in Thailand. Leveraging operating room integration (ORI) and cutting-edge technology, Helion simplifies op...

2024-07-30 10:23 4329

NCCN and Medlive Renew Collaboration to Enhance Cancer Care in China

United States-based National Comprehensive Cancer Network strengthens relationship with Chinese medical platform Medlive to broaden access to eminent oncology guidelines inChina PLYMOUTH MEETING, Pa., July 30, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®), an alliance o...

2024-07-30 09:02 3696

NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs)

TEL-AVIV, Israel, July 30, 2024 /PRNewswire/ -- Neurim Pharmaceuticals ("Neurim") announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending an extension to the existing ind...

2024-07-30 09:00 4728

CSafe launches reusable Silverpod pallet shipper to help pharma companies save on disposal costs and hit sustainability targets

New pallet improves cost and operational efficiency while reducing environmental impact; includes real-time visibility with cloud connectivity Key features include: * Made of fully reusable components and recyclable PCM (phase change material) refrigerants * New integrated real-time tracking...

2024-07-30 02:00 4043

Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p<0.0001), which was sustained at week 52 (p<0.0001) -- -- Obicetrapib lowered LDL-C by 36.3% at week 12 and by 41.5% at week 52,...

2024-07-29 23:18 4276
1 ... 160161162163164165166 ... 381

Week's Top Stories